The Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today released its 2021 Annual Report, showcasing a year of significant advances and forecasting continued growth ahead. The 2021 Report presents important milestones for the sector over the past year, including the approval of six new gene, cell, and tissue-based therapies, record sector investment, and promising early-stage clinical readouts.
2021 was an auspicious year for the cell and gene therapy sector. ARM shared highlights from the investment, clinical, and scientific landscape, as well as a look at what’s ahead for 2022 and beyond, at the Cell & Gene Therapy State of the Industry Briefing. Following the presentation, two expert led panels discussed gene therapy for rare disease and next-generation therapies for cancer.
ARM and NIIMBL Release Project A-Gene to Bring QbD Principles to Gene Therapy Manufacturing
The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) today released Project A-Gene, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case study of a viral vector commonly used in gene therapies.
This presentation provides an overview of the investment, clinical, and scientific environment for cell and gene therapy, including major milestones from 2021 and a look ahead at what 2022 has in store.
ARM’s annual State of the Industry briefing provides an update on global financings, clinical development, public policy considerations, and other regenerative medicine sector trends. A recording of the presentation is available here.